Strategic Partnership: Heidelberg Pharma and Huadong

27/28 February 2022
Safe Harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
Welcome to our Call on the Strategic Partnership with Huadong

Speaker:

Dr. Jan Schmidt-Brand
CEO / CFO

Q&A:

Dr. George Badescu
CBO

Prof. Dr. Andreas Pahl
CSO

Prof. Dr. Christof Hettich
Chairman
Managing Partner of dievini
Our Mission

New option in cancer therapy with a unique mode of action

- Overcome resistance mechanisms
- Kill dormant tumor cells

Heidelberg Pharma’s ADC approach – ATACs®

- Amanitin from the death cap mushroom as toxic payload
- Inhibition of RNA Polymerase II kills cancer cells
- Mode of action enables use of biomarker
- Optimized linker design
- Specifically engineered antibodies
- Development for hematological and solid tumor indications

ADC technology

- Antibodies that specifically target a tumor-associated antigen
- Loaded with a highly effective toxin that they deliver to tumor cells
- Enable targeted therapy in oncology
- Improved therapeutic window and fewer side effects

ADCs bring toxins specifically to cancer cells, HDP’s ADCs with amanitin as payload – ATACs®
# Growing Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proprietary ATAC pipeline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple myeloma (DLBCL/CLL)</td>
<td></td>
<td></td>
<td>III</td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-102</td>
<td>CD37</td>
<td>NHL</td>
<td></td>
<td></td>
<td>II</td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-103</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td>III</td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-104</td>
<td>n/a</td>
<td>Undisclosed tumor indication</td>
<td></td>
<td></td>
<td></td>
<td>Huadong (Asia)</td>
</tr>
<tr>
<td>HDP-XX</td>
<td>n/a</td>
<td>Solid / Hematological tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## ATAC collaborations

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGTA-ATACs</td>
<td>CD117,</td>
<td>HSCs, Conditioning programs for blood cancers</td>
<td></td>
<td></td>
<td></td>
<td>Magenta</td>
</tr>
<tr>
<td></td>
<td>CD45</td>
<td>and genetic diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-ATACs</td>
<td>n/a</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td>Takeda/Millenium</td>
</tr>
</tbody>
</table>

## Licensed legacy assets (non-ATACs)

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLX250-CDx, TLX250, RHB-107, LH011</td>
<td>Different oncological indications; COVID-19</td>
<td></td>
<td></td>
<td>In clinical Phase I-III development</td>
<td>Telix, RedHill, Link Health</td>
</tr>
</tbody>
</table>
Rationale for the Strategic Partnership

- Deal is providing a strong partner in Asia
- Funding will support advancing development of current product candidates and broadening the pipeline
- Support Heidelberg Pharma’s global product development strategy in Asia
- Build a robust ADC product pipeline with best-in-class potential

Exclusive License agreement for the development and commercialization of ATAC® product candidates in Asia, including China, Hong Kong, South Korea and others, deal value USD 930 million

Huadong will also invest up to EUR 105 million in equity in Heidelberg Pharma
Partner Huadong Medicine – China Grand Enterprise: A Major Pharma Player in China and Beyond

- China Grand Enterprise (CGE) is a leading private conglomerate in China active in different sectors.
- Healthcare is the key business of CGE, including chemical pharmaceuticals, biopharmaceuticals, herbal medicines and medical devices, CGE has 50+ pharmaceutical subsidiaries.
- Consolidated revenue: ~USD30 bn (2020)

<table>
<thead>
<tr>
<th>Entity</th>
<th>Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huadong Medicine</td>
<td>100%</td>
</tr>
<tr>
<td>Grand Pharmaceutical Group Limited</td>
<td>100%</td>
</tr>
<tr>
<td>Lei Yun Shang</td>
<td></td>
</tr>
<tr>
<td>Grand Life Sciences Group Limited</td>
<td></td>
</tr>
</tbody>
</table>

Huadong Medicine is a subsidiary of CGE with consolidated annual sales of over USD5.2 bn (2020)

- Pharmaceutical R&D, Manufacturing, Sales & Marketing
- Overseas Equity Investment Platform
- Other Subsidiaries
Huadong Medicine at a Glance

- Headquartered in Hangzhou China
- Founded in 1993
- IPO in 1999
  - Ticker: SZ.000963
  - 42% owned by CGE
- 3 Major Businesses:
  - Pharmaceutical
  - Distribution
  - Aesthetics
- 2020 Revenue USD5.2 bn
  - Pharmaceutical USD1.7 bn
- 11,000 + Employees

Patient Centered. Science Driven.
Huadong Manufacturing Sites

Hangzhou, Headquarter
Center of management, marketing, R&D, and manufacture

Jiangdong, Hangzhou
Microbial, Macromolecular API, Oral Solid Preparations, Powder Injection Preparations, etc

Yancheng, Jiangsu
Synthetic, Microbial Fermentative API, Preparations for Topical Use Drugs

Xi’an, Shanxi
Synthetic API, Innovative Narcotic Drugs R&D and manufacture

5 API certified by CEP

7 API certified by FDA

2 Formulations certified by EMA
Huadong Sales Network in China

- 6,000+ Medical Reps
- 2,400+ Tier 3 Hospitals
- 16,000+ Tier 2 and Tier 1 Hospitals
- 52,000+ Clinics
- 260,000+ Retail Pharmacies
Huadong is Building an ADC Ecosystem

- Nanobody
- Bispecific
- Masking

- CDMO
- ROR1 ADC

- Mirvatuximab Soravtansine

- Development
- Manufacturing
- Marketing & sales in China and APAC

Feeding Huadong’s pipeline and supporting its ADC infrastructure in Europe and beyond
# ATAC® Multi-Program Exclusive Licensing Agreement

<table>
<thead>
<tr>
<th>HDP-101 (BCMA ATAC)</th>
<th>HDP-102 (CD-37 ATAC)</th>
<th>Next 2 ATAC candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDP-103 (PSMA ATAC)</td>
<td>HDP-104 (undisclosed)</td>
<td></td>
</tr>
</tbody>
</table>

- **Exclusive development and commercialization rights**
- **Exclusive option**
- **Right of first negotiation (ROFN)**

For select countries in Asia¹, excludes Japan:

<table>
<thead>
<tr>
<th>Terms</th>
<th>Terms</th>
<th>Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Upfront payment of USD 20 m</td>
<td>• Undisclosed option exercise fee</td>
<td>• Terms to be negotiated at the time of triggering ROFN</td>
</tr>
<tr>
<td>• Milestone payments of up to USD 449 m</td>
<td>• Total of up to USD 461 m</td>
<td></td>
</tr>
<tr>
<td>• Royalties on sales, single to low double-digit percentage for each candidate</td>
<td>• Royalties on sales, single to low double-digit percentage for each candidate</td>
<td></td>
</tr>
</tbody>
</table>

---

¹ People’s Republic of China, Hong Kong, Macao, Taiwan, South Korea, Indonesia, Singapore, The Philippines, Thailand, Bangladesh, Bhutan, Brunei, Myanmar, Cambodia, Laos, Malaysia, Maldives, Mongolia, Nepal and Vietnam; excludes Japan, India, Pakistan, Sri Lanka
Four Key ATAC® Programs Part of Strategic Collaboration

**HDP-101 (BCMA-ATAC)***

- Lead indication: Multiple myeloma (MM)
- BCMA (B-cell maturation antigen) overexpression and activation are associated with MM
- Phase I/IIa clinical trial ongoing in USA and Germany

**HDP-102: CD37-ATAC***

- Target indication: non-Hodgkin lymphoma (NHL)
- CD37 is overexpressed on B-cell lymphoma cells
- Potential IND application in 2023

**HDP-103: PSMA-ATAC***

- Target indication: Metastatic castration-resistant prostate cancer (mCRPC)
- PSMA is overexpressed in nearly all cases of prostate cancer
- Potential IND application in 2023

**HDP-104: undisclosed target**

China is one of the major global and fastest growing markets
### Clear Responsibilities in a Well-defined Process

<table>
<thead>
<tr>
<th>Heidelberg Pharma</th>
<th>Huadong</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development and commercialization outside Asia</td>
<td>Participation to global clinical trials</td>
</tr>
<tr>
<td>Clinical trial and commercial supply of products</td>
<td>Commercialization of products in Asia</td>
</tr>
</tbody>
</table>

Heidelberg Pharma to become a global ADC player
Further Support via Equity Investment - Huadong to Become a Major Shareholder

Investment agreement between Heidelberg Pharma, Huadong Medicine Investment Holding (Huadong) and main shareholder dievini Hopp BioTech holding (dievini)

- Huadong will invest up to EUR 105 m in Heidelberg Pharma via a planned rights issue and purchase of shares from dievini:
  - Rights issue of up to EUR 80 m planned, based on prospectus and using authorized capital: Up to 12.4 m shares @ EUR 6.44, same as last financing round in April 2021
  - Huadong to participate in rights issue and acquire up to ~26% of Heidelberg Pharma shares outstanding, dievini to offer its subscription rights as needed
  - Huadong plans additional share purchase from dievini of up to 9% of shares outstanding to reach total shareholding of up to 35% of share capital post rights issue
- Huadong to become 2\textsuperscript{nd} largest shareholder in Heidelberg Pharma, dievini to remain largest shareholder.

<table>
<thead>
<tr>
<th>Rights issue</th>
<th>using authorized capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>EUR 80 m</td>
</tr>
<tr>
<td>Number of shares</td>
<td>12,408,649</td>
</tr>
<tr>
<td>Share price</td>
<td>EUR 6.44</td>
</tr>
<tr>
<td>Subscription ratio</td>
<td>11:4</td>
</tr>
<tr>
<td>Planned new share capital</td>
<td>46,584,458</td>
</tr>
</tbody>
</table>
Approval Process and Scenario Planning

Required approvals:
- German Federal Ministry of Economic Affairs and Climate Action according to Foreign Trade and Payments Ordinance (Außenwirtschaftsverordnung)
- Chinese law for Overseas Direct Investment (ODI)
- BaFin (German Federal Financial Supervisory Authority) exemption from potential mandatory takeover offer for Huadong

Scenario planning:
- If no approval until 27th July 2022, Huadong can extend the Long Stop Date until 27th October 2022.
  - Huadong and dievini will grant 12-months loans of EUR 10 m each at same terms.
  - Loans will be repaid in cash.
- If the approvals are not granted until the Long Stop Date, no shares will be issued to and acquired by Huadong.
  - Then dievini might consider participating in the rights issue and exercise a part of its subscription rights to fulfil its financing commitment (17th February 2022).
A Transformative Deal with a Strong Partner: Supporting our Strategy to Become a Global ADC Player

Significant immediate strengthening of cash position*

Adds another dedicated, long-term investor to our strategic shareholder base

Enables accelerated development and potentially shorter time to market and broadening of pipeline

Potential broadening of the collaboration to further exploit synergies

Success-based milestones and royalties offer potential for ongoing cash infusion to support business for the long term

Resource sharing via joint clinical development means less use of our own resources

Secures market access in China, one of the major global and growing markets, and Asian markets

*Financial guidance to be provided on 24th March with 2022 financial results
Contact Us

Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg, Germany
Website: www.heidelberg-pharma.com

George Badescu, CBO
Tel.: +49 6203 10090
gregor.badescu@hdpharma.com

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Tel.: +49 89 210 28840
Email: katja.arnold@mc-services.eu

Ticker data
ISIN: DE000A11QVV0
Symbol: HPHA
Reuters: HPHA.DE
Bloomberg: HPHA.GY